Open AccessEnhanced cytotoxicity against solid tumors by bispecific antibody-armed CD19 CAR T cells: a proof-of-concept study
Author(s) -
Archana Thakur,
John Scholler,
Dana Schalk,
Carl H. June,
Lawrence G. Lum
Publication year - 2020
Publication title -
journal of cancer research and clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.338
H-Index - 94
eISSN - 1432-1335
pISSN - 0171-5216
DOI - 10.1007/s00432-020-03260-4
Subject(s) - cd19 , cytotoxicity , chimeric antigen receptor , antigen , cancer research , medicine , antibody , cell culture , t cell , immunology , immune system , biology , in vitro , biochemistry , genetics
Although adoptive cell therapy with chimeric antigen receptor (CAR)-engineered T cells has shown durable clinical efficacy in patients with CD19 + B cell malignancies, the application of this approach to solid tumors is challenging. The goal of this proof-of-concept study was to investigate whether loading of CD19-CAR T cells (CART19) with anti-HER2 or anti-EGFR bispecific antibodies (BiAb) will target HER2 + /EGFR + CD19 - targets and signal the intracellular domain of CAR without engaging antigen-specific CD19 ScFv of CAR T cells.